成人复发或转移性软组织肉瘤经皮冷冻消融的安全性和有效性
单机构回顾性研究纳入141例成人患者、217次经皮冷冻消融、250个复发或转移性软组织肉瘤病灶,评估局部控制的安全性和有效性。冰球充分覆盖率为82%(204/250),并发症率2%(4/217),1年局部无进展生存率86%、2年80%。多因素分析显示冰球覆盖不充分(HR=7.34)及腹膜(HR=3.63)或腹膜后(HR=3.71)位置相对肺部与局部进展风险升高独立相关。
要点
- 冰球覆盖不充分者局部进展风险升高(HR=7.34),术中应确保冰球覆盖全部病灶并各维度至少5 mm边缘。
- 腹膜(HR=3.63)或腹膜后(HR=3.71)病灶相对肺部病灶局部进展风险更高。
- 并发症率2%(4/217),含3例主要并发症和1例次要并发症。
核心结论
- 对经手术、放疗或全身治疗后的复发或转移性软组织肉瘤,经皮冷冻消融具有良好的安全性和有效性;作者认为可考虑用于治疗难治性软组织肉瘤的局部控制。
研究设计与样本
- 单机构回顾性研究,纳入2016年1月至2023年4月接受经皮冷冻消融以实现复发或转移性软组织肉瘤局部控制的成人患者141例(中位年龄66岁;女90例、男51例),共217次消融、250个病灶;由一名介入放射科医生复阅术中图像评估冰球覆盖;参考标准为病历记录的并发症和结局;主要疗效终点为1年局部无进展生存率。
诊断标准与关键数值
- 冰球充分覆盖定义为冰球覆盖全部病灶并在所有维度达到5 mm或以上边缘,本组82%(204/250)病灶达到充分覆盖;1年局部无进展生存率86%、2年80%;1年无化疗生存率45%、2年31%;1年总生存率89%、2年80%;中位消融后随访25个月(范围3-80个月);并发症率2%(4/217),包括3例主要并发症和1例次要并发症。
临床应用与阅片要点
- 术中图像复阅应确认冰球覆盖全部病灶并在所有维度达到5 mm或以上边缘,因覆盖不充分与局部进展风险升高独立相关(HR=7.34);腹膜(HR=3.63)或腹膜后(HR=3.71)病灶相对肺部病灶局部进展风险更高;作者认为经皮冷冻消融可考虑用于治疗难治性软组织肉瘤的局部控制。
局限性
- 本文为单机构回顾性研究。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Treatment options are limited in patients with recurrent or metastatic disease after initial treatment of soft-tissue sarcoma (STS) by surgical resection, radiation, or systemic therapy. Percutaneous cryoablation may provide a complementary minimally invasive option in this setting. OBJECTIVE. The purpose of this article was to assess the safety and efficacy of percutaneous cryoablation performed for local control of treatment-refractory recurrent or metastatic STS. METHODS. This single-institution retrospective study included adult patients who underwent percutaneous cryoablation from January 2016 to April 2023 to achieve local control of recurrent or metastatic STS after earlier treatment (surgery, radiation, or chemotherapy). For each treated lesion, a single interventional radiologist rereviewed intraprocedural images to assess for adequate coverage by the ice ball of the entire lesion and a 5-mm or greater margin in all dimensions. Complications and outcomes were extracted from medical records. The primary end point for procedure efficacy was 1-year local progression-free survival. RESULTS. The study included 141 patients (median age, 66 years; 90 women, 51 men) who underwent 217 cryoablation procedures to treat 250 recurrent or metastatic STS lesions. The most common STS histologic types were leiomyosarcoma (56/141) and liposarcoma (39/141). Lesions had a mean long-axis diameter of 2.0 cm (range, 0.4-11.0 cm). Adequate ice-ball coverage was achieved for 82% (204/250) of lesions. The complication rate was 2% (4/217), including three major complications and one minor complication. Patients' median postablation follow-up was 25 months (range, 3-80 months). Local progression-free survival rate was 86% at 1 year and 80% at 2 years. The chemotherapy-free survival rate was 45% at 1 year and 31% at 2 years. The overall survival (OS) rate was 89% at 1 year and 80% at 2 years. In Kaplan-Meier analysis, leiomyosarcoma, in comparison with liposarcoma, had significantly higher local progression-free survival but no significant difference in OS. In multivariable analysis, factors independently associated with an increased risk for local progression included inadequate ice-ball coverage (HR = 7.34) and a lesion location of peritoneum (HR = 3.63) or retroperitoneum (HR = 3.71) relative to lung. CONCLUSION. Percutaneous cryoablation has a favorable safety and efficacy profile in patients with recurrent or metastatic STS after earlier treatments. CLINICAL IMPACT. Percutaneous cryoablation should be considered for local control of treatment-refractory STS.
引用
- Pal K, Awad A, Yevich S, et al. Safety and Efficacy of Percutaneous Cryoablation for Recurrent or Metastatic Soft-Tissue Sarcoma in Adult Patients. AJR Am J Roentgenol. 2024. PMID: 39082849. doi:10.2214/AJR.24.31490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。